Theriva Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-25.65	-18.35	-19.69	-14.27	-10.04	Upgrade
Depreciation & Amortization	0.14	0.14	0.09	0.09	0.2	Upgrade
Asset Writedown & Restructuring Costs	6.92	-	-	-	-	Upgrade
Stock-Based Compensation	0.67	0.55	0.48	0.42	0.35	Upgrade
Other Operating Activities	0.26	-3.64	0.85	0.17	0.11	Upgrade
Change in Accounts Payable	0.12	-0.16	-0.39	-0.36	-1.43	Upgrade
Change in Other Net Operating Assets	0.6	2.47	-0.42	1.07	-1.35	Upgrade
Operating Cash Flow	-16.94	-19	-19.08	-12.89	-12.17	Upgrade
Capital Expenditures	-0	-0.2	-0.12	-0.01	-0.01	Upgrade
Cash Acquisitions	-	-	-3.86	-	-	Upgrade
Investing Cash Flow	-0	-0.2	-4.4	-0.01	-0.01	Upgrade
Long-Term Debt Repaid	-0.07	-0.08	-1.38	-	-	Upgrade
Net Debt Issued (Repaid)	-0.07	-0.08	-1.38	-	-	Upgrade
Issuance of Common Stock	5.56	2.22	-	74	3.36	Upgrade
Repurchase of Common Stock	-	-	-0.29	-	-	Upgrade
Other Financing Activities	-	-1.52	-3	-	-	Upgrade
Financing Cash Flow	5.5	0.63	-1.93	74	3.36	Upgrade
Foreign Exchange Rate Adjustments	-0.13	-0.03	-0.03	-	-	Upgrade
Net Cash Flow	-11.57	-18.61	-25.44	61.1	-8.82	Upgrade
Free Cash Flow	-16.94	-19.2	-19.2	-12.9	-12.18	Upgrade
Free Cash Flow Per Share	-12.56	-29.80	-31.31	-26.47	-160.13	Upgrade
Levered Free Cash Flow	-10.55	-14.41	-10.42	-7.51	-8.3	Upgrade
Unlevered Free Cash Flow	-10.55	-14.41	-10.42	-7.51	-8.3	Upgrade
Change in Net Working Capital	-0.35	1.09	-1.16	-0.93	2.67	Upgrade

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q